Search bioRxiv⌕ Search

bioRxiv · 10.1101/2022.08.30.505459

Automatic Sample Segmentation & Detection of Parkinson's Disease Using Synthetic Staining & Deep Learning

Abstract

The identification of Parkinsons Disease (PD) from post-mortem brain slices is time consuming for highly trained neuropathologists, often taking many hours per case. In this study, we demonstrate fully automatic PD detection, from single 1000um regions, from sections spanning from the dorsal motor nucleus of the vagus nerve to the frontal cortex. This is achieved via image processing and statistical methods, with improved accuracy demonstrated when using machine learning. Digitised stained brain sections were processed via a deep neural network to produce re-coloured, or synthetically stained, images which were then filtered and passed to a secondary network for classification. We demonstrate state-of-the-art PD detection (>90% accuracy on single 1000um regions), with the ability to perform binary classification on high resolution sections within minutes, in addition to demarcating regions of interest to the pathologist for manual visual verification. Executive SummaryThe identification of Parkinsons Disease (PD) from post-mortem brain slices is time consuming for highly trained neuropathologists, often taking many hours per case. Accurate classification and stratification of PD is critical for the confirmation that the brain donor suffered from PD and to maximise the potential usefulness of the brain in research studies to better understand the causes of PD and foster drug development. Parkinsons UK Brain Bank, at Imperial College London, has produced a dataset containing digitised images of brain sections immunostained for the protein alpha-synuclein (-syn), the pathological marker of PD; along with control cases from healthy donors. This dataset is much larger (over 400 cases), more consistent, and of higher quality (all have been stained with the same protocol and imaged within the same laboratory) than has been documented elsewhere in the literature; including those found in a meta-analysis study on detection of neurological disorders containing over 200 papers (Lima et al., 2022). The project team, consisting of neuroscientists and subject matter experts from: Imperial, NHS AI Lab Skunkworks, Parkinsons UK, and Polygeist have undertaken a 12 week project to examine the possibility of producing a Proof-of-Concept (PoC) tool to automatically load, enhance and ultimately classify those brain sections containing -syn. The initial focus of the project was to make a tool that could make a biomarker of PD, -syn, more visible to the pathologist; saving time in searching for the protein manually. This goal was quickly reached, producing a tool that could synthetically stain the -syn, marking regions of interest in a high-contrast bright green, making them quickly identifiable for the pathologist. Statistical analysis of the synthetically stained images showed that very few regions in the control group were stained compared to the PD group, raising the possibility that an automatic classifier could be developed, which became a stretch goal for the project. A bespoke neural network model was designed that processed the synthetically stained segments of each immunostained section and produced a binary judgement (whether a segment contains PD pathology or not). The model achieved >90% sensitivity for PD detection, much higher than is reported for neuropathologists (~60% sensitivity when searching for -syn patches across all stages, Signaevsky et al., 2022). While expert raters are still more precise (~6% better than the model), the model performed ~20% better than expert raters when considering precision and recall. The key output of the project is an open-source PoC tool that can automatically classify PD from digitised images of brain sections with accuracy that is approaching viability for real world applications. An MIT Licensed code repository has been released, containing all of the model development code, along with associated documentation, to allow others to build on the project teams work. This report summarises the scientific and engineering process undertaken through the development of the PoC tool.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Pearce, B. M., Coetzee, P. L., Rowland, D., Dexter, D. T., Gveric, D. O., Gentleman, S.. 2022-09-01. Automatic Sample Segmentation & Detection of Parkinson's Disease Using Synthetic Staining & Deep Learning. https://doi.org/10.1101/2022.08.30.505459

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

SilencioM: silencing connected interfering oligonucleotides against MAPT as a potential disease modifying therapeutic for tauopathies

Tauopathies are a diverse group of neurodegenerative diseases whose pathogenesis involves brain accumulation of misfolded, pathological tau (Microtubule Associated Protein Tau, MAPT). More than twenty tauopathies have been identified thus far that collectively impact millions of people worldwide, of which the most common is Alzheimer's disease (AD). Despite substantial efforts to develop drugs for tauopathies, no effective treatments currently exist, highlighting the urgent need for therapeutics to combat these prevalent and ruinous neurodegenerative diseases. Strategies that target tau are likely to have the greatest impact since tau is the proximal cause of their pathogenesis. Small interfering RNAs (siRNAs) have emerged as a powerful class of precision therapeutics that silence disease-causing genes through RNA interference with favorable safety profiles. Delivery challenges are rapidly being addressed, and siRNA-based approaches are poised to transform the therapeutic landscape of neurological diseases. In this study, we describe SilencioM (Silencing connected interfering oligonucleotides against MAPT) and show its efficacy in markedly reducing tau pathology after a single intracerebroventricular injection in PS19 mice, a mouse model of severe tauopathy. SilencioM targets human, primate, rat and mouse ortholog genes; thus, the same compound can proceed from efficacy studies to Investigational New Drug Application (IND)-enabling studies. SilencioM is simple to manufacture and is administered without encapsulation in lipid nanoparticles and without requirements for lipophilic conjugation, making it a promising candidate for further development as a novel therapeutic for tauopathies, including AD.

pathology↗

SilencioMA: A single compound that targets both MAPT and APP as a potential disease modifying therapeutic for Alzheimer's Disease

Alzheimer's Disease (AD) is the most common age-related neurodegenerative disease and the leading cause of dementia worldwide. AD pathogenesis involves aggregation of amyloid-beta (A{beta}), produced from amyloidogenic proteolytic processing of Amyloid Precursor Protein (APP), and accumulation of misfolded, pathological tau (Microtubule Associated Protein Tau, MAPT). Current efforts focus on developing disease modifying therapeutics (DMTs) against single targets: A{beta} or tau. However, DMTs that concurrently target both tau and A{beta} are likely to have the greatest impact since they target both culprits of AD pathogenesis. Here we describe the development of SilencioMA, a single compound that targets both MAPT and APP messenger RNAs (mRNAs) based on silencing connected interfering oligonucleotides against MAPT and APP. Cerebrospinal fluid (CSF) administration of SilencioMA reduces A{beta} and tau and pathology after a single intracerebroventricular injection in 5XFAD/PS19 mice, an animal model of severe amyloidosis and tauopathy. SilencioMA does not rely on lipid nanoparticles or lipophilic conjugates for CSF administration. At the same time its modular design permits conjugation of ligands that facilitate transcytosis through the blood brain barrier, allowing systemic administration. Our findings provide proof-of-concept for a strategy that targets the dual A{beta} and tau pathologies of AD, and establishes a compelling foundation for further development of SilencioMA as a next-generation DMT for AD.

pathology↗

TREM2-stimulated, PDGF-dependent macrophage-fibroblast crosstalk induces beneficial plaque remodeling in clonal hematopoiesis

Background: In Jak2V617F clonal hematopoiesis, inflammatory signaling suppresses macrophage TREM2 and promotes features of plaque instability, while therapeutic TREM2 agonism reverses plaque instability by increasing fibroblasts and fibrous cap formation. We tested whether macrophage-derived PDGFB and stromal cell PDGFR? signaling mediate this response. Methods: Low allele burden (LAB) Jak2V617F atherosclerosis models were combined with inducible Pdgfb deletion in CX3CR1-lineage monocytes/macrophages or Pdgfra deletion in Col1a2-lineage fibroblast-enriched stromal cells. Mice were treated with the TREM2 agonist 4D9. Plaque composition, macrophage-fibroblast interactions, and aortic stromal cell populations were analyzed. Human WT and JAK2V617F iPSC-derived macrophages were used for validation. Results: TREM2 activation with 4D9 increased macrophage PDGFB production and promoted fibrous cap formation in LAB Jak2V617F atherosclerosis. Deletion of Pdgfb in CX3CR1-lineage cells markedly attenuated the 4D9-mediated increase in fibrous cap area and lesional PDGFR?+ cells, establishing macrophage-derived PDGFB as a key signal for the stromal response. Consistently, Col1a2-lineage Pdgfra deletion abolished the 4D9-induced fibrous cap response without significantly altering lesion or necrotic core area. Single cell RNA-seq identified increased Fmod+ and CD26/Dpp4+ fibroblast populations associated with 4D9 treatment. Fmod+ fibroblasts represented an abundant matrix-associated population, whereas CD26+ fibroblasts showed greatest enrichment, prominent extracellular matrix, collagen organization, and matrix-remodeling programs that were enhanced by 4D9 and attenuated by Pdgfra deletion. The stromal response was also associated with reduced macrophage migration-related programs and predicted chemokine communication from CD26+ fibroblasts to macrophages which was verified by macrophage migration studies. Moreover, stromal Pdgfra deletion increased lesional CCR2+ and CCR5+ macrophages. Conclusions: In a CH model of inflammatory atherosclerosis, TREM2 activation promotes a macrophage PDGFB-stromal PDGFR? pathway that expands Fmod+ and CD26+ fibroblast populations and increases fibrous cap matrix formation. CD26+ fibroblasts impair macrophage chemotaxis in a DPP4-dependent manner, suggesting reciprocal macrophage-fibroblast communication that coordinates matrix remodeling and inflammatory cell trafficking in the plaque.

pathology↗